Clinical Trial Detail

NCT ID NCT01391143
Title Safety Study of MGA271 in Refractory Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors MacroGenics
Indications

lung non-small cell carcinoma

melanoma

renal cell carcinoma

triple-receptor negative breast cancer

prostate carcinoma

head and neck cancer

bladder carcinoma

Therapies

MGA271

Age Groups: adult

No variant requirements are available.